Literature DB >> 20941502

Influence of the vascular endothelial growth factor on the development of severe pre-eclampsia or HELLP syndrome.

Stefanie Bussen1, Dieter Bussen.   

Abstract

PURPOSE: The aim of this study was to compare the maternal serum concentrations of the vascular endothelial growth factor (VEGF) in patients whose pregnancies were complicated by pre-eclampsia or HELLP syndrome with those of healthy pregnant controls and to study its relationship with the hormonal and nutritive function of the placenta.
METHODS: The study group consisted of 30 primaparae who suffered from either severe pre-eclampsia (n = 16) or from HELLP syndrome (n = 14). 30 healthy pregnant woman of the same gestational age served as control group. Maternal serum VEGF concentrations were determined by using a commercially available Sandwich immunoassay (Quantikine(®), R&D Systeme, Wiesbaden, Germany). Estradiol, estriol and progesterone serum levels were measured by performing a radioimmunoassay (Biermann, Bad Nauheim, Germany).
RESULTS: The mean serum VEGF concentration of the study group (172.0 ± 98.9 pg/ml) was significantly increased, compared with the mean serum VEGF concentration of the control group (41.4 ± 30.5 pg/ml) (U test: P < 0.001). In the subgroup of the study patients with HELLP syndrome, significantly lower VEGF levels were measured than in patients suffering from severe pre-eclampsia (109.2 ± 68.5 pg/ml vs. 219.0 ± 72.9. U test: P < 0.05). In all study and control patients, a significantly positive correlation between serum estradiol and VEGF concentration could be found (Spearman's rank correlation: P < 0.05).
CONCLUSIONS: An increased placental expression due to local hypoxia and an increased extraplacental production, e.g., in endothelial cells of the fetal or maternal vascular system, in macrophages or in smooth muscle cells, could be discussed as causes for the raised serum VEGF concentration in patients suffering from severe pre-eclampsia or HELLP syndrome.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20941502     DOI: 10.1007/s00404-010-1704-x

Source DB:  PubMed          Journal:  Arch Gynecol Obstet        ISSN: 0932-0067            Impact factor:   2.344


  6 in total

Review 1.  A Narrative Review of Placental Contribution to Adverse Pregnancy Outcomes in Women With Polycystic Ovary Syndrome.

Authors:  Angela S Kelley; Yolanda R Smith; Vasantha Padmanabhan
Journal:  J Clin Endocrinol Metab       Date:  2019-11-01       Impact factor: 5.958

2.  Positive versus negative effects of VEGF165 on Ca2+ signaling and NO production in human endothelial cells.

Authors:  Derek S Boeldt; Jennifer Krupp; Fu-Xian Yi; Nauman Khurshid; Dinesh M Shah; Ian M Bird
Journal:  Am J Physiol Heart Circ Physiol       Date:  2016-11-11       Impact factor: 4.733

Review 3.  Secretory products of the corpus luteum and preeclampsia.

Authors:  María M Pereira; Monica Mainigi; Jerome F Strauss
Journal:  Hum Reprod Update       Date:  2021-06-22       Impact factor: 15.610

Review 4.  Significance of vascular endothelial growth factor in growth and peritoneal dissemination of ovarian cancer.

Authors:  Samar Masoumi Moghaddam; Afshin Amini; David L Morris; Mohammad H Pourgholami
Journal:  Cancer Metastasis Rev       Date:  2012-06       Impact factor: 9.264

Review 5.  HELLP Syndrome-Holistic Insight into Pathophysiology.

Authors:  Aida Petca; Bianca Corina Miron; Irina Pacu; Mihai Cristian Dumitrașcu; Claudia Mehedințu; Florica Șandru; Răzvan-Cosmin Petca; Ioana Cristina Rotar
Journal:  Medicina (Kaunas)       Date:  2022-02-21       Impact factor: 2.430

Review 6.  Physiology and Pathophysiology of Steroid Biosynthesis, Transport and Metabolism in the Human Placenta.

Authors:  Waranya Chatuphonprasert; Kanokwan Jarukamjorn; Isabella Ellinger
Journal:  Front Pharmacol       Date:  2018-09-12       Impact factor: 5.810

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.